Literature DB >> 6940191

Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a.

C Gerard, T E Hugli.   

Abstract

A functionally active and potentially lethal fragment of the fifth component of complement (C5) is generated during complement activation in serum from animals of various species. This factor, termed the "classical" anaphylatoxin, was isolated from porcine serum and was identified chemically as the des-Arg derivative of the well-characterized C5a molecule. Unlike the C3a and C4a anaphylatoxins, porcine C5a does not require the COOH-terminal arginyl residue for spasmogenic activity. Further degradation of porcine des-Arg(74)-C5a by carboxypeptidase Y removed glycine-73 and leucine-72 and decreased the intrinsic spasmogenic activity by >90%. Hence, we conclude that, although the arginyl residue is not essential, the COOH-terminal sequence Leu-Gly-Arg contributes structural information that accounts for >90% of C5a activity. Human des-Arg(74)-C5a, like its porcine counterpart, has instrinsic anaphylatoxin activity; however, higher concentrations were needed to contract the guinea pig ileal tissue (i.e., 1 muM for human des-Arg(74)-C5a versus 1 nM for porcine des-Arg(74)-C5a). Furthermore, the des-Arg form of human C5a was only 0.1% as active as porcine des-Arg(74)-C5a for enhancing vascular permeability in guinea pig skin. In addition to these biological differences, numerous chemical differences exist between the human and porcine des-Arg(74)-C5a molecules, the most prominent feature being an oligosaccharide entity associated uniquely with the human C5a. When the oligosaccharide unit of human des-Arg(74)-C5a was removed by glycosidases, leaving a single glucosamine residue attached to the side chain of asparagine-64, activity was enhanced. The human des-Arg(74)-C5a molecule devoid of the complex oligosaccharide unit exhibited 10-fold stronger spasmogenic activity and 20- to 50-fold greater permeability-enhancing activity than did human des-Arg(74)-C5a containing the oligosaccharide. Consequently, the oligosaccharide associated with human C5a modulates or suppresses potentially harmful activities of this anaphylatoxin. The relatively high levels of spasmogenic activity associated with porcine des-Arg(74)-C5a indicate that this factor is poorly controlled by endogenous serum carboxypeptidase, whereas human C5a is virtually inactivated by the enzyme. Hence, the influence of this oligosaccharide in suppressing human des-Arg(74)-C5a activity is of major physiologic importance in protecting man from potentially toxic effects of this complement factor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6940191      PMCID: PMC319229          DOI: 10.1073/pnas.78.3.1833

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

Review 1.  The anaphylatoxin-forming system.

Authors:  W Vogt
Journal:  Ergeb Physiol       Date:  1967

2.  Formation of anaphylatoxin in human serum.

Authors:  W Vogt; G Bodammer; E Lufft; G Schmidt
Journal:  Experientia       Date:  1969

3.  Endo-beta-N-acetylglucosaminidase acting on carbohydrate moieties of glycoproteins. Purification and properties of the enzyme from Diplococcus pneumoniae.

Authors:  N Koide; T Muramatsu
Journal:  J Biol Chem       Date:  1974-08-10       Impact factor: 5.157

4.  Apparent dispensability of the carbohydrate moiety of human interferon for antiviral activity.

Authors:  S Bose; D Gurari-Rotman; U T Ruegg; L Corley; C B Anfinsen
Journal:  J Biol Chem       Date:  1976-03-25       Impact factor: 5.157

5.  Partial characterization of human C5a anaphylatoxin. I. Chemical description of the carbohydrate and polypeptide prtions of human C5a.

Authors:  H N Fernandez; T E Hugli
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

6.  Primary structural analysis of the polypeptide portion of human C5a anaphylatoxin. Polypeptide sequence determination and assignment of the oligosaccharide attachment site in C5a.

Authors:  H N Fernandez; T E Hugli
Journal:  J Biol Chem       Date:  1978-10-10       Impact factor: 5.157

7.  Anaphylatoxin inactivator of human plasma: its isolation and characterization as a carboxypeptidase.

Authors:  V A Bokisch; H J Müller-Eberhard
Journal:  J Clin Invest       Date:  1970-12       Impact factor: 14.808

8.  Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin.

Authors:  T E Hugli; B W Erickson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-05       Impact factor: 11.205

9.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307

10.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more
  20 in total

1.  Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus.

Authors:  J F Bohnsack; K W Mollison; A M Buko; J C Ashworth; H R Hill
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

2.  Differential effects of the complement peptides, C5a and C5a des Arg on human basophil and lung mast cell histamine release.

Authors:  E S Schulman; T J Post; P M Henson; P C Giclas
Journal:  J Clin Invest       Date:  1988-03       Impact factor: 14.808

3.  Loss and recovery of sensitivity of guinea-pig isolated ileum to the spasmogenic action of the complement peptide C5adesArg.

Authors:  B Damerau; J Roesler; W Vogt
Journal:  Br J Pharmacol       Date:  1985-01       Impact factor: 8.739

Review 4.  Biological properties of human C5a: selected in vitro and in vivo studies.

Authors:  K B Yancey
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

5.  Receptors for complement components in inflammation.

Authors:  A Sobel; C Blanc; A Cattaneo; M Moisy; M Lopez-Trascasa; J J Bourgarit; Y Gabay
Journal:  Agents Actions       Date:  1983-08

6.  Role of histamine in the spasmogenic effect of the complement peptides C3a and C5a-desArg (classical anaphylatoxin).

Authors:  J Sorgenfrei; B Damerau; W Vogt
Journal:  Agents Actions       Date:  1982-04

7.  A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma.

Authors:  Mark Dysinger; Mark Ma
Journal:  AAPS J       Date:  2018-10-02       Impact factor: 4.009

8.  Attachment of human C5a des Arg to its cochemotaxin is required for maximum expression of chemotactic activity.

Authors:  H D Perez; D E Chenoweth; I M Goldstein
Journal:  J Clin Invest       Date:  1986-12       Impact factor: 14.808

9.  Isolation of three separate anaphylatoxins from complement-activated human serum.

Authors:  T E Hugli; C Gerard; M Kawahara; M E Scheetz; R Barton; S Briggs; G Koppel; S Russell
Journal:  Mol Cell Biochem       Date:  1981-12-04       Impact factor: 3.396

10.  Novel neutrophil chemotactic factor derived from human peripheral blood mononuclear leucocytes.

Authors:  E Kownatzki; A Kapp; S Uhrich
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.